Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 193-200 , December 2010

Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators

  • Kristina L. Demas, BA

      Affiliations

    • George Washington School of Medicine, Washington, DC
    • ,
  • Brendan T. Keenan, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
    • ,
  • Daniel H. Solomon, MD, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
    • ,
  • Jinoos Yazdany, MD, MPH

      Affiliations

    • UCSF, Division of Rheumatology, San Francisco, CA
    • ,
  • Karen H. Costenbader, MD, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
    • Corresponding Author InformationAddress reprint reprints to: Karen H. Costenbader, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115

References 

  1. Yazdany J. Strategies for preventive care in systemic lupus erythematosus. J Musculoskel Med. 2008;25:316–320
  2. Yazdany J, MacLean CH. Quality of care in the rheumatic diseases: current status and future directions. Curr Opin Rheumatol. 2008;20(2):159–166
  3. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44(7):1496–1503
  4. Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005;80(2):194–202
  5. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–1389
  6. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention?. Ann Rheum Dis. 1995;54(1):66–68
  7. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221–225
  8. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1384–1396
  9. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331–2337
  10. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887–1893
  11. Mosca M, Bombardieri S. Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 2007;25(6 Suppl 47):107–113
  12. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42(9):1785–1796
  13. Crossing the Quality Care Chasm: The IOM Health Care Quality Initiative. July 20, 2006;In
  14. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, Maclean CH, Wofsy D, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009;61(3):370–377
  15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725
  16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277
  17. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163
  18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
  19. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415
  20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269(23):3015–3023
  21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA. 2003;289(19):2560–2572
  22. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy?. J Obstet Gynaecol Can. 2008;30(12):1146–1148
  23. Ginzler EM, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Bailliere Clin Rheumatol. 1998;12(3):495–510
  24. Bruce IN, Gladman DD, Urowitz MB. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol. 1998;16(4):435–440
  25. Hallegua DS, Wallace DJ. How accelerated atherosclerosis in SLE has changed our management of the disorder. Lupus. 2000;9(3):228–231
  26. Lockshin MD, Salmon JE, Roman MJ. Atherosclerosis and lupus: a work in progress. Arthritis Rheum. 2001;44(10):2215–2217
  27. Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001;13(5):341–344
  28. Ahmann AJ. Guidelines and performance measures for diabetes. Am J Manag Care. 2007;13(Suppl 2):S41–S46
  29. http://www.ama-assn.org/ama/pub/category/2946.html(accessed January 2009)
  30. Watson KE. The JUPITER trial: How will it change clinical practice?. Rev Cardiovasc Med. 2009;10(2):91–96
  31. www.rheumatology.org/RCR2009;Accessed December 15, 2009

 Supported by NIH Grants P60 AR047782, K24 AR055989-01, BIRCWH K12 HD051959 (supported by NIMH, NIAID, NICHD, and OD). Ms. Demas was the recipient of a Lupus Foundation or New England/Arthritis Foundation of Massachusetts jointly sponsored summer student award.

PII: S0049-0172(10)00005-3

doi: 10.1016/j.semarthrit.2010.01.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 193-200 , December 2010

Article Tools